meningococcal group B vaccine (recombinant, adsorbed) · Medicine question

What meningococcal disease risk remains after Trumenba vaccination in people receiving eculizumab?

Name: What meningococcal disease risk remains after Trumenba vaccination in people receiving eculizumab?
Published: 2026-11-08T14:29:00.684Z

iatroX medicinesPublished 8 November 2026

The answer

Answer

People receiving eculizumab remain at increased risk of invasive disease caused by Neisseria meningitidis serogroup B even if they develop antibodies following Trumenba vaccination.

Sources for this answer

Trumenba suspension for injection in pre-filled syringePfizer Limited · emc · SmPC §4.4 Special warnings and precautions for use · Version 17Document updated 27 August 2026

Sources checked 8 November 2026

loading page…

Answer

Sources for this answer

Answer

Sources for this answer

More questions about meningococcal group B vaccine (recombinant, adsorbed)